Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1I2 | O75469 | 2/20 | 0.58 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.53 |
| ▸ | GPR119 | Q8TDV5 | 11/20 | 0.38 |
| ▸ | MEN1 | O00255 | 4/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12909920 | 1.00 | NR1I2 (0.58) | NR1I2CYP2E1GPR119MEN1KMT2A | |
| SCHEMBL939092 | 0.96 | NR1I2 (0.56) | NR1I2CYP2E1GPR119MEN1KMT2A | |
| SCHEMBL939093 | 0.96 | NR1I2 (0.56) | NR1I2CYP2E1GPR119MEN1KMT2A | |
| SCHEMBL12909592 | 0.96 | NR1I2 (0.56) | NR1I2CYP2E1GPR119MEN1KMT2A | |
| SCHEMBL12909593 | 0.96 | NR1I2 (0.56) | NR1I2CYP2E1GPR119MEN1KMT2A | |
| SCHEMBL15005752 | 0.96 | NR1I2 (0.56) | NR1I2CYP2E1GPR119MEN1KMT2A | |
| SCHEMBL1055096 | 0.96 | NR1I2 (0.56) | NR1I2CYP2E1GPR119MEN1KMT2A | |
| SCHEMBL939293 | 0.94 | NR1I2 (0.62) | NR1I2CYP2E1GPR119MEN1KMT2A | |
| SCHEMBL12909601 | 0.92 | NR1I2 (0.56) | NR1I2CYP2E1GPR119 | |
| SCHEMBL12439623 | 0.92 | NR1I2 (0.58) | NR1I2CYP2E1GPR119MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140030223-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2014-01-30 | — | — | US | disclosed |
| US-8569302-B2 | Inhibitors of flaviviridae viruses | GILEAD SCIENCES, INC. (US) | 2013-10-29 | — | — | US | disclosed |
| EP-2475657-B1 | 5-ALKINYLTHIEN-2-YLCARBOXYLIC ACIDS AS INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES INC (US) | 2013-06-12 | — | — | EP | disclosed |
| US-20110020278-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | GILEAD SCIENCES, INC. (US) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140030223-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | HAVCR2, CYP2F1, CYP4F3 | NR1I2 88/4885CYP2E1 6/4885GPR119 2226/4885 |
| US-20110020278-A1 | INHIBITORS OF FLAVIVIRIDAE VIRUSES | HAVCR2, CYP2F1, CYP4F3 | NR1I2 88/4885CYP2E1 6/4885GPR119 2226/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.